Caims et al CAMIAT Pilot Study 551 select patients according to the presence of ventricular arrhythmia, and it showed a trend in favor of drug therapy. Subsequently, another trial of aprindine has shown a trend in favor of the drug,19 and a Swiss study20 has reported a significant benefit of amiodarone in the reduction of sudden and cardiac mortality. On the other hand, the Cardiac Arrhythmia Suppression Trial21 was recently terminated early because of excessive sudden death and all-cause mortality among patients receiving flecainide and encainide, although the ethmozine limb continues.
The present study was undertaken before a planned multicenter trial to assess the efficacy of amiodarone in reducing mortality from cardiac arrhythmias among patients who have survived AMI accompanied by frequent or repetitive VPDs. The specific objectives of this pilot study were to evaluate the efficacy of amiodarone for the suppression of VPDs, the toxicity of amiodarone, the rates of outcome events, and the feasibility of the planned multicenter trial. This trial (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial [CAMIAT] ) is now under way in 35 Canadian hospitals. Methods The pilot study was conducted from 1986 through 1988 in the five coronary care units (CCUs) of the university teaching hospitals in Hamilton, Ontario, Canada, a city with a population of 390,000. All patients were screened by study nurses who assigned a diagnosis of AMI only after documentation of at least two of three standard criteria (characteristic pain of at least 15 minutes' duration, elevation of cardiac enzymes to more than twice the upper limit of normal, and development of electrocardiographic evidence of MI).
Those patients who survived for 6 days following CCU admission became eligible for 24-hour ambulatory monitoring, which was performed as long as 30 days after onset of AMI. The analysis was conducted using either a Hittman Compuscan or a Personal Computers for Medicine system. Every VPD, couplet (VPD followed by a second VPD after an interval of 600 msec or less), and ventricular tachycardia (VT) run (three or more consecutive VPDs at a mean RR interval of 600 msec or less) were visualized and hand counted unless there was a very high frequency of VPDs. Each report as well as extensive sample electrocardiographic strips were overread by one of the investigators (J.A.C. or S.J.C.).
The inclusion criteria for the study were 1) AMI 6-45 days before study entry, during which either of the following were detected on 24-hour ambulatory electrocardiography-a mean of at least 10 VPDs/hr (at least 18 hours of monitoring required) or at least one run of VT; and 2) age of 18 years or more.
All patients who satisfied these inclusion criteria were then evaluated for exclusion criteria of 1) contraindications to amiodarone (previous intolerance or current therapy, waking bradycardia, PR interval of 220 msec or more, second-or third-degree atrioventricular block, prolonged QT interval, peripheral neuropathy, chronic or acute hepatitis, interstitial pulmonary fibrosis, hyperthyroidism, or hypothyroidism); 2) requirement of antiarrhythmic therapy (run of VT for 6 beats or more and rate of 100 min' or more, atrial or ventricular arrhythmia that in the opinion of the treating physician required treatment with antiarrhythmic drugs other than ,1-blockers or digitalis), tricyclic antidepressant drugs, or phenytoin; 3) medical factors (NYHA class IV congestive heart failure, CCVS class IV angina, noncardiac illness likely to shorten survival significantly, and women of childbearing potential); and 4) geographic or other social factors making study participation impractical.
Eligible patients who gave informed consent were randomly allocated in a double-blind fashion in a 2: 1 ratio to amiodarone or an identical-appearing placebo in 200-mg tablets. The loading dosage of study medication was 10 mg/kg/day to the nearest 100 mg for 3 weeks. Clinical evaluations, trough plasma amiodarone concentrations, and Holter monitors were done weekly for 3 weeks. Dosage reductions were made as necessary for drug intolerance or potentially serious side effects. VPD suppression was defined as the absence of VT and an 80% reduction from baseline frequency of 30 VPDs/hr or more or a 90% reduction from baseline frequency of 10 or more to less than 30 VPDs/hr.
If at 3 weeks the arrhythmia was suppressed, the dosage was decreased to 400 mg/day for body weight of 70 kg or more or 300 mg/day for body weight of less than 70 kg. If the arrhythmia was not suppressed, the loading dose was continued for an additional 3 weeks, at which time it was reduced to 400 or 300 mg/day. Subsequently, patients were followed at 2-month intervals for a total of 24 months. At each follow-up visit, procedures performed included history and physical examination, 24-hour Holter monitor, trough amiodarone and desthylamiodarone (DEA) plasma concentrations, electrocardiography, aspartate amino transferase test (AST), alkaline phosphatase, bilirubin, thyroxine (T4), and thyroidstimulating hormone (TSH). Diffusing capacity for carbon monoxide (DCO) was undertaken approximately every 2 months, and a chest radiograph was done every 4 months.
The intent was to modify study drug dosage in relation to arrhythmia suppression, trough plasma amiodarone levels (sham plasma levels were generated for placebo patients), and side effects. Therefore, if a patient exhibited suppression on two successive Holter monitors done 2 Observed changes from baseline in mean VPD rates have been compared between groups over time using analysis of variance for repeated measures. The occurrence of major and minor adverse experiences has been summarized on an "ever-reported" basis, and the incidence was compared between treatment groups using a x2 test. Although this pilot study was not designed to reliably compare outcome rates between amiodarone and placebo groups, the small number of reported events have been summarized, and the observed risk reduction has been computed.
Results

Screening and Patient Entry
During the first year of screening, 821 patients experienced AMI, 86.3% survived to hospital discharge, and of these patients, 87.6% underwent Holter monitoring. A total of 77 patients (5.5% of all AMI survivors) entered the study during the 2-year study period and were followed for a maximum of 2 years (mean, 20 months).
The baseline characteristics of the amiodarone and placebo groups (Table 1) were reasonably comparable. The relatively high incidence of anterior MI, previous MI, congestive heart failure, and mean VPD frequency characterizes cohorts with rather poor prognoses.
Amiodarone Dosage, Amiodarone Plasma Levels, and VPD Suppression
The planned loading regimen was achieved in 73% of the amiodarone patients and 76% of the placebo patients. Mean amiodarone dosages were 345 mg/day at 2 months, 179 mg/day at 12 months, and 152 mg/day at 24 months. Figure 1 and compare patients still receiving amiodarone (i.e., not permanently discontinued) with those on placebo.
Early Discontinuation of Study Drug
Permanent study drug discontinuation for reasons other than death or resuscitated ventricular fibrillation (VF) occurred in 35% of patients in the amiodarone group and 34% of patients in the placebo group. Twenty-three patients in the amiodarone group (48%) and 15 patients in the placebo group (52%) had their study drug permanently discontinued early. The primary reasons for these discontinuations are given in Table 2 .
Major Adverse Experiences
Major adverse experiences reported in the two treatment groups are summarized in Table 3 There was only one patient, who we believe was noncompliant, in whom plasma concentrations were unexpectedly low for the prescribed dosage of amiodarone. Seven patients on amiodarone and two on placebo permanently discontinued study drug because they or their physician were unwilling for them to continue, even though important side effects were not elicited. Patients were not allowed to enter the trial if they were on any antiarrhythmic agent other than digoxin, /3-blocker, or calcium antagonist. There were two patients who were resuscitated from VF, both of whom were found to be receiving amiodarone, and both were maintained on open-label amiodarone. No other patients were placed on amiodarone or other antiarrhythmic drug.
Outcomes
The outcomes according to treatment allocation are listed in Table 5 . The composite outcome of arrhythmic death or resuscitated VF occurred in three amiodarone patients (6%) and four placebo patients (14%); the corresponding numbers for overall mortality were five (10%) and six (21%), respectively, an observed risk reduction of more than 50%.
Discussion
The presence of frequent or repetitive VPDs on 24-hour ambulatory monitoring done relatively soon after MI has been established as an independent and clinically important prognostic factor in survivors of AMI.1-57-9 These findings constitute the rationale for recent studies of antiarrhythmic drug therapy in such patients. [19] [20] [21] 23 The present pilot study focused on the potential of amiodarone for use in such patients, and the results are consistent with those from the recently reported Swiss trial20 in which reductions of sudden death and all-cause mortality were observed among amiodarone-treated patients with VPDs after AMI.
The very large distribution space of amiodarone, the relatively slow accumulation of amiodarone in this space, and the antiarrhythmic properties of the major amiodarone metabolite, DEA, necessitate the use of a loading dose.24 When patients with symptomatic VT or resuscitated VF are treated with amiodarone, a relatively large loading dose is generally used. However, in this pilot study, even with a low loading dose, VPD suppression was achieved in 63% of patients within 1 week and 85% of patients within 2 weeks.
The reduction of VPD frequency and complexity on Holter monitoring has been widely used to evaluate antiarrhythmic drug efficacy. However, the high spontaneous variability in day-to-day VPD frequency and the even greater variability in month-to-month VPD frequency25-29 necessitate very conservative criteria for judging VPD suppression on Holter. The 95% confidence limits for spontaneous variability from day-to-day frequency encompass a 65-90% decrease in VPD frequency and are even wider for Holters done several months apart. Although drug efficacy can be clearly demonstrated in groups of patients allocated to active drug or placebo, judgments about efficacy are uncertain in individual patients. In the present study, conservative criteria for arrhythmia suppression were used, yet on average, 38% of placebo patients showed apparent suppression of VPDs at any given follow-up point. Therefore, the effect attributable to amiodarone at 2 weeks, for example, is less than the observed 85% and is more like 58%, the difference between that observed with amiodarone therapy (85%) and that observed with placebo (27%).
The mean plasma levels of amiodarone and DEA obtained in the present study were generally within the usual therapeutic range, although appropriate plasma levels and maintenance dosages are controversial.30 32 It was not uncommon for patients to exceed the upper limit of 2.0 mg/l during loading, and dosage reductions produced appropriate decreases in plasma levels. Low plasma levels were observed during the second year of the study, when the mean dosage was less than 200 mg/day. At this point, recurrence of arrhythmia was observed in several patients, and drug dosage was increased to regain suppression.
The principal limitation to the wider use of amiodarone, particularly in North America, has been its toxicity profile. The major concern is pulmonary toxicity, but neurological, hepatic, thyroid, and visual toxicities have also been of concern, and the minor gastrointestinal and skin reactions and insomnia have also been factors. 24, 33 It is generally agreed that less problematic toxicity occurs when amiodarone is used as a first-line drug at a relatively low dosage and in patients who are not necessarily severely ill. [33] [34] [35] [36] Series in which toxicity is rather frequent and serious are likely to use amiodarone as an agent of late or last resort for patients who are often very ill, and consequently the dosages are rather high and treatment may be maintained even in the presence of some toxicity. [37] [38] [39] In the present study, no patient died as a result of amiodarone toxicity. Possible pulmonary toxicity occurred in three patients (6.3%), although the link was not definitely established in two of them, and there was almost certainly no link in the third. Hepatic enzyme increase was equally common among amiodarone and placebo patients and always resolved on stopping the drug. Chemical hypothyroidism was common, occurring in 25% of amiodarone patients but in no placebo patient. Long-term follow-up of these patients will determine whether normal thyroid function resumes after completion of the course of amiodarone therapy. Proarrhythmia is a recognized hazard of most antiarrhythmic drugs, although it is probably rare with amiodarone therapy. 24 The three patients who developed apparent proarrhythmia in the present study were found to be receiving placebo. Abnormalities in day vision occurred but were not attributable to amiodarone. Minor side effects were common, particularly during the loading phase. However, apart from skin manifestations, they were no more common among the amiodarone patients than among those receiving placebo, which emphasizes the importance of placebo controls for the objective assessment of adverse experiences. Although minor side effects often led to dosage modifications, they rarely resulted in permanent discontinuation of the study drug.
Permanent early discontinuation for reasons other than death or resuscitated VF occurred in 17 of 48 patients (35%) in the amiodarone group and 10 of 29 patients (34%) in the placebo group. These are similar to the rates observed previously in a study of antiplatelet drugs in patients with unstable angina40 and in a Swiss trial of amiodarone after MI.20 They are slightly higher than rates in trials of ,B-blocker therapy after MI.41,42 The pattern of discontinuation was such that approximately half of the amiodarone patients who eventually terminated early had received at least 1 year of treatment, indicating that they may have benefited from therapy during the period of highest risk after MI and, in addition, would have had detectable plasma levels of amiodarone and DEA for several months after drug discontinuation.
Hinkle and Thaler22 developed a clinical classification of cardiac death, distinguishing patients in whom death occurred abruptly without prior collapse of the circulation (arrhythmic death) from those in whom the pulse ceased only after the peripheral circulation had collapsed (deaths in circulatory failure). That 
